Trial Profile
A Preliminary Study Assessing the Feasibility of Estimating and Determining Amyloid Burden from Florbetapir PET Images without Using Target and Reference Regions based on the Deep Learning 3D Convolutional Neural Network Approach
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2018
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Diagnostic use
- 05 Oct 2018 New trial record